

A Phase 2, Randomized, Single-Center, Controlled Study to Evaluate the Safety, Immunogenicity and Priming Ability of the Chiron Meningococcal C Conjugate Vaccine in Adults at Risk for Meningococcal Serogroup C Exposure or Disease

IRB# 2003-016

Principal Investigator: Dan Granoff, MD

Synopsis:

The primary safety objective is to evaluate the safety of a single dose of Chiron Meningococcal C Conjugate Vaccine when administered to adults at risk for meningococcal serogroup C exposure or disease.

The primary immunogenicity objective is to compare the memory serum antibody response to *Neisseria meningitidis* serogroup C as measured by an enzyme-linked immunosorbent assay (ELISA), at 7 days following exposure to a reduced “booster” dose of a licensed meningococcal polysaccharide vaccine (Menomune®) subsequent to conjugate vaccine primes (Chiron Meningococcal C Conjugate Vaccine or Prevnar®), in adults at risk for meningococcal serogroup C exposure or disease.